Capital Advisors Ltd. LLC Has $344,000 Holdings in Pfizer Inc. (NYSE:PFE)

Capital Advisors Ltd. LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 4.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,566 shares of the biopharmaceutical company’s stock after selling 616 shares during the period. Capital Advisors Ltd. LLC’s holdings in Pfizer were worth $344,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Tallon Kerry Patrick bought a new position in Pfizer in the fourth quarter valued at about $509,000. Brighton Jones LLC grew its position in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its position in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares during the last quarter. Stonebridge Financial Group LLC bought a new position in Pfizer in the fourth quarter valued at about $193,000. Finally, Sovran Advisors LLC bought a new position in Pfizer in the fourth quarter valued at about $922,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock opened at $24.46 on Thursday. The business’s 50 day simple moving average is $22.96 and its 200 day simple moving average is $24.98. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The stock has a market capitalization of $139.04 billion, a PE ratio of 17.34, a PEG ratio of 0.64 and a beta of 0.57. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. During the same period in the prior year, the business posted $0.82 earnings per share. The firm’s revenue was down 7.8% on a year-over-year basis. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.03%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PFE. The Goldman Sachs Group restated a “neutral” rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target on the stock. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.